Gandotinib - Eli Lilly

Drug Profile

Gandotinib - Eli Lilly

Alternative Names: LY2784544

Latest Information Update: 27 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly
  • Class 2 ring heterocyclic compounds; Antineoplastics; Small molecules
  • Mechanism of Action Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Myeloproliferative disorders
  • No development reported Myelofibrosis; Solid tumours

Most Recent Events

  • 22 Feb 2018 Eli Lilly completes a phase I trial in Myeloproliferative disorders in USA (PO) (NCT01134120)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Myelofibrosis in USA (PO, Capsule)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top